Healthcare firm Aurobindo Pharma rose 2.11 percent to close at Rs 193.30 on the Bombay Stock Exchange on Tuesday as the company has received final approval from the US Food & Drug Administration to manufacture and market Rizatriptan Benzoate Tablets.
The company said the product was ready for launch. "Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) is the generic equivalent of Merck and company's Maxalt tablets and is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 6 to 17 years old," Aurobindo said in a release.
The annual sale of product is approximately USD 300 million for 12 months ending March 2012, according to IMS. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad.
Aurobindo has a total of 171 ANDA approvals from USFDA.
Aurobindo Pharm stock price
On November 30, 2015, Aurobindo Pharma closed at Rs 810.65, down Rs 7.65, or 0.93 percent. The 52-week high of the share was Rs 1540.55 and the 52-week low was Rs 490.50.
The company's trailing 12-month (TTM) EPS was at Rs 25.30 per share as per the quarter ended September 2015. The stock's price-to-earnings (P/E) ratio was 32.04. The latest book value of the company is Rs 94.68 per share. At current value, the price-to-book value of the company is 8.56.
READ MORE ON Aurobindo Pharma
Set email alert for
ADS BY GOOGLE
video of the day
Mkt resilient at current level; bullish auto: ICICI Pru AMC